Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01255891
Recruitment Status : Unknown
Verified August 2009 by McGill University.
Recruitment status was:  Recruiting
First Posted : December 8, 2010
Last Update Posted : December 8, 2010
Information provided by:
McGill University

Brief Summary:
To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post radical prostatectomy patients with high risk pathological features for failure. To determine the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and clinical progression rate at 5 years.

Condition or disease Intervention/treatment Phase
Adenocarcinoma of the Prostate Radiation: Androgen suppression plus radiation therapy Phase 2

Detailed Description:
Same as brief Summary

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate
Study Start Date : January 2010
Estimated Primary Completion Date : August 2014
Estimated Study Completion Date : January 2015

Arm Intervention/treatment
Adjuvant suppression plus radiation therapy
Radiation: Androgen suppression plus radiation therapy
Adjuvant androgen suppression plus radiation therapy

Primary Outcome Measures :
  1. to determine the rate of local and distance failure at 5 years [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (N0) or lymph node status pathologically unknown (undissected pelvic lymph nodes [Nx]), i.e. lymph node dissection is not required;
  2. Any type of radical prostatectomy will be permitted, including retropubic, perineal laparoscopic or robotically assisted. If performed, the number of lymph nodes removed per side of the pelvis and the extent of the pelvic lymph node dissection (obturator vs. extended lymph node dissection) should be noted. There is no time limit for the date of radical prostatectomy.
  3. A post-radical prostatectomy entry PSA of > 0 and < 1 ng/ml at least 6 weeks after prostatectomy and within 30 days of registration.
  4. One of the following pathologic/chemical classifications:

    • T3N0/Nx disease with or without positive surgical margin; or;
    • Gleason score of 8 or more;
    • Pre prostatectomy PSA > 20 ng/ml
  5. KPS > 70
  6. Age ≥ 18;
  7. No distant metastases, based upon the following minimum diagnostic workup:
  8. History/physical examination (including digital rectal exam) within 8 wks prior to registration;
  9. A CT scan or MRI of the abdomen and pelvis within 120 days prior to registration;
  10. Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis.
  11. Adequate bone marrow function, within 90 days prior to registration, defined as follows:

    • Platelets ≥ 100,000 cells/mm3 based upon CBC;
    • Hemoglobin ≥ 10.0 g/dl based upon CBC
    • AST or ALT < 2 x the upper limit of normal within 90 days prior to registration;
  12. Patients must sign a study-specific informed consent prior to study entry.


  1. A palpable prostatic fossa abnormality/mass suggestive of recurrence, unless shown by biopsy under ultrasound guidance not to contain cancer;
  2. N1 patients are ineligible, as are those with pelvic lymph node enlargement ≥ 1.5 cm in greatest dimension by CT scan or MRI of the pelvis, unless the enlarged lymph node is sampled and is negative;
  3. Androgen deprivation therapy started prior to prostatectomy for > 6 months duration;
  4. Androgen deprivation therapy started after prostatectomy and prior to registration;
  5. Prior pelvic radiotherapy;
  6. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 5 years (for example, carcinoma in situ of the oral cavity is permissible);
  7. Severe, active co-morbidity, defined as follows:

    • History of inflammatory bowel disease;
    • History of hepatitis B or C; Blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis.
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
    • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; AST or ALT are required; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol.
    • Prior allergic reaction to the study drug(s) involved in this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01255891

Layout table for location contacts
Contact: Tamim Niazi, Dr. 514-340-8248

Layout table for location information
Canada, Quebec
Montreal General Hospital Recruiting
Montreal, Quebec, Canada, H3G 1Y6
Contact: Luis Souhami, MD    514-934-8040   
Contact: Audrey Fernandes, Ph.D.    514-934-1934 ext 43128   
Sub-Investigator: Luis Souhami, MD         
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Beatrice Fournier, Ph.D.    514-340-8248   
Principal Investigator: Tamim Niazi, MD         
Sponsors and Collaborators
McGill University
Layout table for investigator information
Principal Investigator: Tamim Niazi, MD McGill University Department of Oncology
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Tamim Niazi, Principal Investigator, McGill University Department of Oncology Identifier: NCT01255891    
Other Study ID Numbers: McG 0913
First Posted: December 8, 2010    Key Record Dates
Last Update Posted: December 8, 2010
Last Verified: August 2009
Keywords provided by McGill University:
high risk localized adenocarcinoma of the prostate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs